Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23
Supplementary editorial provided by OncologySTAT
TAKE-HOME MESSAGE
Identification of the MLL fusion partner is critical for risk stratification in patients with t(11q23)-positive AML.
STUDY IN CONTEXT
Several... (Source: OncologySTAT Journal Scans)...
POSTED 06/30/2009 at 09:58 AM --
|
Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis
We here report a case of rheumatoid arthritis (RA) with acute myeloid leukemia with multilineage dysplasia (AML-MLD) and Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD). A 64-year-old healthy man suffered from arthralgia, and was ultimately diagnosed with RA based on bilateral hand X-rays showing mild swelling and destruction of the MP and PIP joints. Since non-steroidal anti-inflammatory drugs were not effective, prednisolone and bucillamine were administered. After 4 months, his pancytopenia gradually progressed, and bone marrow (BM) examination revealed the presence of AML-MLD. A chemotherapeutic drug regimen including low-dose cytarabine led to nearly complete remission, but several weeks later, high fever and dyspnea suddenly appeared. Computer tomograp......
POSTED 06/29/2009 at 06:00 PM --
|
[Leukemia and Bone Marrow Transplantation] Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Conclusion
MN1 expression independently predicts outcome in CN-AML patients. The MN1 gene- and microRNA-expression signatures suggest biologic features that could be exploited as therapeutic targets. (Source: Journal of Clinical Oncology)...
POSTED 06/28/2009 at 06:00 PM --
|
Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement.
CONCLUSIONS: Quality of reporting in RCTs focusing on myeloid malignancies remains unsatisfactory. Further improvement of reporting is necessary to assess the validity of clinical research.
PMID: 19523596 [PubMed - in process] (Source: Annals of Epidemiology)...
POSTED 06/27/2009 at 09:05 PM --
|
FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype
No abstract. (Source: American Journal of Hematology)...
POSTED 06/26/2009 at 06:00 PM --
|
Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer
Abstract: Smoking is associated with both acute myeloid leukemia (AML) and lung cancer. We therefore searched our database for concomitant presentation of AML and lung cancer. Among 775 AML cases and 5225 lung cancer cases presenting to Roswell Park Cancer Institute between the years January 1992 and May 2008 we found 12 (1.5% of AML cases; 0.23% of lung cancer cases) cases (seven metachronous and five synchronous) with AML and lung cancer. All but one patient were smokers. There were no unique characteristic of either AML or lung cancer in these patients. Nine patients succumbed to AML, one died from an unrelated cause while undergoing treatment for AML, one died of lung cancer and one patient is alive after allogeneic transplantation for AML. In summary, this study supports the need for ......
POSTED 06/26/2009 at 09:24 AM --
|
Total serum tryptase: A predictive marker for KIT mutation in acute myeloid leukemia
Abstract: Human tryptase is a serine protease expressed in mast-cells. We previously observed that AML blast cells, cultured in vitro from a KIT D816Y patient, give rise to adherent cells with mast-cell like phenotype and tryptase was released in the serum-free medium. To correlate total serum tryptase (ts-try) levels with cytogenetic features and KIT mutational status, we analyzed serum samples from AML patients at diagnosis. In 70 out of 155 patients (45%) we detected elevated ts-try (>15ng/mL), significantly linked to t(8;21) (P (Source: Leukemia Research)...
POSTED 06/26/2009 at 09:24 AM --
|
Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia
Abstract: When faced with a life-threatening illness such as acute myeloid leukemia (AML), patients may feel overwhelmed with making treatment decisions. We recruited 31 consecutive English-speaking patients aged ≥50 with newly diagnosed AML. We explored patient information needs, decision-making roles, and perceptions about prognosis. Most patients felt that they had enough information about the diagnosis and treatment options and that the doctor spent the right amount of time with them. The majority of patients preferred a passive or collaborative decision-making role. Almost half the patients did not know their estimated 6-month prognosis, and 17% felt it was 90% or better. (Source: Leukemia Research)...
POSTED 06/26/2009 at 09:24 AM --
|
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST
We report here a case of refractory cytopenia with mutilineage dysplasia (RAEB-1) with monosomy 7 which rapidly transformed into AML in a patient with GIST during imatinib treatment. (Source: Leukemia Research)...
POSTED 06/26/2009 at 09:24 AM --
|
Absence of mutations in the tyrosine kinase and juxtamembrane domains of C-FMS gene in chronic myelomonocytic leukemia (CMML)
The differentiation of macrophages is controlled by the lineage-specific growth macrophage colony stimulating factor-1 (CSF-1), which acts by binding to cell surface receptors (csf-1r) encoded by the C-FMS proto-oncogene. The C-FMS gene is located between 5q33.2 and 5q33.3 and encodes a 972 amino acid transmembrane glycoprotein with tyrosine-kinase activity that is expressed on cells of the monocyte/macrophage lineages. Mutations in this gene have been associated with a predisposition to myeloid malignancies. Mutations at codon 301 [TTG(Leu)] of the C-FMS gene are speculated to induce neoplastic transformation by ligand independence and constitutive tyrosine kinase activity of the receptor, whereas those involving codon 969 [TAT(Tyr)] would suppress its negative regulatory activity. Studie......
POSTED 06/26/2009 at 09:24 AM --
|
Arsenic/tretinoin: Acute myeloid leukaemia: case report.
Page: 9 (Source: Reactions Weekly)...
POSTED 06/26/2009 at 09:16 AM --
|
Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children
Conclusions This therapeutic protocol achieved good oncologic and orthopaedic results. We observed a significant treatment-related toxicity.
Content Type Journal ArticleCategory Research ArticlesDOI 10.1007/s12094-009-0373-3Authors
Arturo Muñoz, Hospital Ramón y Cajal-Universidad de Alcalá Servicio de Pediatría Ctra. de Colmenar Viejo km. 9,100 ES-28034 Madrid SpainJosé Alfaro, Hospital Virgen del Rocío Sevilla SpainNuria Pardo, Hospital San Pablo Barcelona SpainPurificación García-Miguel, Hospital La Paz Madrid SpainVíctor Quintero, Hospital Niño Jesús Madrid SpainLuis Gros, Hospital Valle de Hebrón Barcelona SpainCarmen Melero, Hospital 12 de Octubre Madrid SpainMaría Jesús Antuña, Hospital Central de Asturias Oviedo, Asturias SpainGuillermo Ocete, Hosp......
POSTED 06/26/2009 at 03:23 AM --
|
RUNX genes find a niche in stem cell biology
The RUNX family of transcriptional regulators are well conserved throughout the animal kingdom, from the simple nematode worm Caenorhabditis elegans to vertebrates. Interest in the RUNX genes emerged principally as a result of the finding that chromosomal translocations disrupting RUNX protein function are observed in a large number of patients suffering with acute myeloid leukemia (AML). In the 20 years that RUNX genes have been under investigation, they have emerged as central players in the control of developmental decisions between proliferation and differentiation in a wide variety of biological situations. This review focuses on recent data highlighting the roles of RUNX genes in stem cells and illustrates the diversity of processes in which the RUNX proteins play a critical role. In......
POSTED 06/25/2009 at 06:00 PM --
|
Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement
Conclusions: Quality of reporting in RCTs focusing on myeloid malignancies remains unsatisfactory. Further improvement of reporting is necessary to assess the validity of clinical research. (Source: Annals of Epidemiology)...
POSTED 06/25/2009 at 03:43 AM --
|
Bacterial pneumonia following bone marrow transplantation: HRCT findings
CONCLUSIONS: The most common HRCT findings in our patient sample were air-space consolidation, small centrilobular nodules and ground-glass opacities, most often in the central and peripheral regions of the middle and lower lung zones.OBJETIVO: Descrever os achados de TCAR em pacientes com pneumonia bacteriana após transplante de medula óssea (TMO). MÉTODOS: Estudo retrospectivo com 30 pacientes diagnosticados com pneumonia bacteriana, documentada com TCAR do tórax realizada em até 24 h do início dos sintomas, e com diagnóstico comprovado com base em cultura positiva de escarro ou de aspirado brônquico associada à cultura positiva de líquido pleural ou de sangue dentro de uma semana após o início dos sintomas. Foram avaliados 20 pacientes masculinos e 10 femininos, com mediana ......
POSTED 06/25/2009 at 03:23 AM --
|
Two-hit model of leukemogenesis in the evolution of polycythemia vera to acute myeloid leukemia
We report a case of PV with evolution to AML in which it was possible to demonstrate the two-hit model of leukemogenesis: one mutation confers proliferative advantage and another interferes with differentiation. Case: A 55-year-old female patient was diagnosed with PV in 2002 and treated with phlebotomies and hydroxyurea. In 2006, there was progression topost-polycythemic fibrosis with AML one year later. She presented the JAK2V617F mutation. The result of karyotyping performed at diagnosis was normal and at transformation, 46,XX,del(20)(q13.1) was detected in 4/20 metaphases. FISH analysis of a stored sample for 20q13 showed the deletion in 20% of interphases confirming the earlier presence of a clonal abnormality that was not detected by karyotyping. The JAK2V617F mutation is sufficient ......
POSTED 06/25/2009 at 02:43 AM --
|
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
This study investigated the immunogenicity of Wilms tumor gene product 1 (WT1)–peptide vaccination in WT1-expressing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients without curative treatment option. Vaccination consisted of granulocyte-macrophage colony-stimulating factor subcutaneously days 1 to 4, and WT1.126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. The initial 9 patients received 4 vaccinations biweekly, then monthly, and the subsequent 10 patients received continual biweekly vaccination. Seventeen AML patients and 2 refractory anemia with excess blasts patients received a median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduc......
POSTED 06/24/2009 at 06:00 PM --
|
Cancer in dyskeratosis congenita
Dyskeratosis congenita (DC) is a rare inherited bone marrow failure syndrome. The spectrum of cancer susceptibility in this disorder of telomere biology has not been described. There were more than 500 cases of DC reported in the literature from 1910 to 2008; the National Cancer Institute (NCI) prospective DC cohort enrolled 50 cases from 2002 to 2007. Sixty cancers were reported in 52 literature cases, while 7 occurred among patients in the NCI DC cohort. The 2 cohorts were comparable in their median overall survival (42 years) and cumulative incidence of cancer (40%-50% by age 50 years). The most frequent solid tumors were head and neck squamous cell carcinomas (40% of patients in either cohort), followed by skin and anorectal cancer. The ratio of observed to expected cancers (O/E ratio)......
POSTED 06/24/2009 at 06:00 PM --
|
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
CEBPA mutations have been associated with improved outcome in adult acute myeloid leukemia (AML). We evaluated the prevalence and prognostic significance of CEBPA mutations in 847 children with AML treated on 3 consecutive pediatric trials. Two types of CEBPA mutations—N-terminal truncating mutations and in-frame bZip-domain mutations—were detected in 38 (4.5%) of 847 patients tested; 31 (82%) of 38 patients with mutations harbored both mutation types. Mutation status was correlated with laboratory and clinical characteristics and clinical outcome. CEBPA mutations were significantly more common in older patients, patients with FAB M1 or M2, and patients with normal karyotype. Mutations did not occur in patients with either favorable or unfavorable cytogenetics. Actuarial event-......
POSTED 06/24/2009 at 06:00 PM --
|
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in the Fms-like tyrosine-3 (FLT3) gene have a dismal prognosis. Here we report compassionate-use results with the multikinase and FLT3-ITD inhibitor sorafenib for the treatment of relapsed or refractory FLT3-ITD–positive AML. Sorafenib induced clinically meaningful and very rapid responses in all 6 patients treated either before (n = 2), after (n = 3), or both before and after (n = 1) allogeneic stem cell transplantation (allo-SCT). Sorafenib-induced remissions facilitated allo-SCT in 2 of the 3 refractory patients. Two of the 4 patients who were treated after allo-SCT survived 216 and 221 days, respectively, whereas the other 2 remain in ongoing complete molecular remission. Sorafenib response was......
POSTED 06/24/2009 at 06:00 PM --
|
